Chang-Sheng Chang

Chang-Sheng Chang

Auto-generated profile, based on publicly available information

Chang-Sheng Chang

Bioinformatics Shared Resource and Integrated Genomics, Georgia Cancer Center, Augusta University, Augusta, GA, 30912, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
MYMiao Yu
Miao Yu
GGGang Guo
Gang Guo
LHLei Huang
Lei Huang
LDLibin Deng
Libin Deng
CCChang-Sheng Chang
Chang-Sheng Chang
YCYan Cui
Yan Cui
CD73, an ecto-5′-nucleotidase (NT5E), serves as an immune checkpoint by generating adenosine (ADO), which suppresses immune activation through the A2A receptor. Elevated CD73 levels in tumor tissues correlate with poor clinical outcomes. However, the crucial source of CD73 activity within the tumor microenvironment remains unspecified. Here, we demonstrate that cancer-associated fibroblasts (CAFs) constitute the prominent CD73hi population in human colorectal cancers (CRCs) and two CD73− murine tumor models, including a modified CRC. Clinically, high CAF abundancy in CRC tissues correlates strongly with elevated CD73 activity and poor prognosis. Mechanistically, CAF-CD73 expression is enhanced via an ADO-A2B receptor-mediated feedforward circuit triggered by tumor cell death, which enforces the CD73-checkpoint. Simultaneous inhibition of A2A and A2B pathways with CD73-neutralization synergistically enhances antitumor immunity in CAF-rich tumors. Therefore, the strategic and effective targeting of both the A2B-mediated ADO-CAF-CD73 feedforward circuit and A2A-mediated immune suppression is crucial for improving therapeutic outcomes.